RuCl2(KTZ)2 acts on the P53 signaling pathway to effectively inhibit the proliferation of a variety of adherent tumor cells, and synergizes the anti-epidermal growth factor receptor (EGFR) inhibitor C225MAb to kill resistant spheroids (Gelfo et al., 2016). This evidence concerns the gene EGFR and neoplasm.